3
Metas de Enfermería

Metas de Enfermería

ABRIL 2016 N° 3 Volumen 19

Evolution of blood pressure in patients undergoing allogeneic transplant and on treatment with cyclosporine

Section: Originals

How to quote

López Gil R, Fernández Roviralta MC. Evolución de la tensión arterial en pacientes en proceso de trasplante alogénico y en tratamiento con ciclosporina. Metas Enferm abr 2016; 19(3): 64-69.

Authors

Raquel López Gil1, Mª Cristina Fernández Roviralta1

Position

1Hematología Clínica. Instituto Catalán de Oncología Duran i Reynals. L’Hospitalet de Llobregat (Barcelona)

Contact address

Raquel López Gil. C/ Usatges de Barcelona, 12, 2-2. 08850 Gavà (Barcelona).

Contact email: rlgil@iconcologia.net

Abstract

Objective: to analyze the evolution pattern of blood pressure and the type of antihypertensive drugs required by patients undergoing allogeneic transplant and on treatment with cyclosporine.
Method: a descriptive study of a series of cases. A non-probability convenience sampling was conducted with a sample of 36 patients. Those persons who had undergone an allogeneic transplant and required treatment with cyclosporine were selected. The variables studied were: gender, age, type of transplant, blood pressure (BP) at baseline, days and way of administration of cyclosporine, as well as pattern and evolution of blood pressure. The toxicity presented was described as associated hypertension according to the Common Terminology Criteria for Adverse Events (CTCAE. v4).
Results: the mean BP was 164.6/89.8, and a higher increase of systolic pressure vs. diastolic pressure was observed. The first hypertension peak appeared before the +13 day. A 66.7% of those patients on antihypertensive treatment required an adjustment or modification of said therapy, and 26.7% required antihypertensive drugs de novo.
Conclusions: monitoring and follow-up of the patient receiving allogeneic transplant of hematopoietic stem cells and, specifically, of the potential complication of arterial hypertension secondary to the administration of cyclosporine, is the responsibility of nurses, both in the Specialized Care and in the Primary Care settings. It is pointed out that any patient, regardless of their gender or type of transplant, can present HT associated with the use of cylosporine and, therefore, nurses must conduct exhaustive monitoring and an adequate follow-up.

Keywords:

Arterial Hypertension; allogeneic transplant; cyclosporine; nursing intervention

Versión en Español

Título:

Evolución de la tensión arterial en pacientes en proceso de trasplante alogénico y en tratamiento con ciclosporina

Artículo completo no disponible en este idioma / Full article is not available in this language

Bibliography

  1. MedlinePlus. Ciclosporina. [Internet]. 2016 [citado 16 marzo 2016]. Disponible en: https://www.nlm.nih.gov/medlineplus/spanish/druginfo/meds/a601207-es.html
  2. Nadège Robert G, Jame Wright M. El tratamiento con ciclosporina aumenta la presión arterial (Revisión Cochrane traducida). [Internet] 2010. [citado 16 mar 2016]. Disponible en: http://www.cochrane.org/es/CD007893/el-tratamiento-con-ciclosporina-aumenta-la-presion-arterial
  3. Curtis JJ, Luke RG, Dubovsky E, Diethelhm AG, Whelchel JD, Jones P. Cyclosporine in therapeutic doses increases renal allograft vascular resistance. Lancet 1986; 2:477-9.
  4. Porter GA, Bennet WM, Sheps SG. Cyclosporine-associated hypertension. Arch Intern Med 1990; 150:280-3.
  5. Golub MS, Beger ME. Direct augmentation by cyclosporine A of vascular contractile response to nerve stimulation. Hypertension. 1987; 9 (suppl 3): 96-100.
  6. Lou LM, Sanjuan A, Paúl J, Peralta C, Bello MJ, Moreno R, Pastor L, Gutiérrez JA. Tratamiento con amlodipino de la hipertensión arterial en el trasplante renal en protocolo con ciclosporina A. Nefrología 1994; XIV (6):701-6.
  7. Van der Schaaf MR, Hené RJ, Floor M, Blankestijn PJ, Koomans HA. Hypertension after renal transplantation: calcium channel or converting enzyme blockade? Hypertension 1995; 25:77-81.
  8. Trasplante de progenitores hematopoyéticos (TPH). Memoria de Actividad. ONT 2011. [Internet] 2012. [citado 16 mar 2016]. Disponible en: http://www.ont.es/infesp/Memorias/Memoria%20TPH%202012.pdf
  9. Lopes JA, Jorge S. Acute kidney injury HCT: incidence, risk factors and outcome. Bone Marrow Transplant 2011; 46:399-408.
  10. Torres Carrete P, González S. Algunos problemas del paciente trasplantado/sometido a TPH. Aula Formativa Hematólogos Jóvenes. 2011.
  11. Bastoni da Silva J, Melo Lima MH, Regina Secoli S. Influence of cyclosporine on the occurrence of nephrotoxicity after allogeneic hematopoietic stem cell transplantation: a systematic review. Rev Bras Hematol Hemoter 2014; 36(5):363-8.
  12. Dalfó A, Gibert E, Vila MA, Sabartés T. Diagnóstico y seguimiento de la hipertensión arterial. ¿Es relevante el papel del personal de enfermería? Aten Primaria. 2000; 26:180-3.
  13. Argómaniz Alutiz J, Cidoncha Moreno MA, Martín Bezos J. Nuevos ámbitos para la práctica enfermera. Metas Enferm 2003; 59:50-5.
  14. Bengston A, Drevenhorn E. The nurse’s role and skills in hypertension care: a review. Clin Nurse Spec. 2003; 17:260-8.
  15. Chummun H. Hypertension: a contemporary approach to nursing care. Br J Nurs. 2009; 18:784-9.
  16. Fernández L, Guerrero L, Segura J, Gorostidi M. Papel del personal de enfermería en el control de la hipertension arterial y en la investigación cardiovascular. Hipertens riesgo vasc 2010; 27 (Supl 1):41-52.
  17. Jódar Solà G, Cadena Andreu A, Parellada Esquius N, Martínez Roldán J. Continuidad asistencial: rol de la enfermera de enlace. Aten Primaria. 2005; 36(10):558-62.
  18. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. U.S. Department of health and human services. National Cancer Institute. May 28, 2009 (v4.03: June 14, 2010).